Financial

With a shift in power in the air, a president in decline, and the case against safety and efficacy for Pfizer's vaccines in certain cohorts building, the political and regulatory future of Pfizer's vaccine program dims. You're invited to join Hedgeye Health Policy analyst Emily Evans as she discusses why Pfizer is bad for America.

Whether due to a loss of funding or the eventual recognition US vaccination policy outlier status, the COVID-19 vaccine gravy train must come to an end. The follow-up question is how does PFE come up with the "$25B in risk adjusted revenue" they promised?

Prime minister revives 1980s ‘greed is good’ mantra as he lauds vaccine rollout at meeting with backbenchers

Investment giants BlackRock and The Vanguard Group stand to benefit from their ownership stakes in most of the corporations that imposed COVID vaccine mandates, and in some of the technology firms developing vaccine passports.

The murky past of Moderna, the UK’s £1billion pharma partner

Vaccine firms can fool governments – but not the markets

Wall Street investors are dumping their Moderna and Pfizer stock faster than the world can drop the mandates. Moderna is down 70 percent from its high, while Pfizer is off

Pfizer hiked its projections for COVID vaccine revenues, telling investors this week it expects booster shots, a vaccine targeting the Delta variant and anticipated authorization of its vaccines for children as young as 6 months will drive revenues higher.

Discover how actuarial data could prompt hedge funds and other astute investors to short sell the Pfizer, BioNTech, and Moderna stocks.

Pfizer's Greed and Recklessness Will Catch Up with Them. That Happened to Purdue Pharma

Discover how actuarial data could prompt hedge funds and other astute investors to short sell the Pfizer, BioNTech, and Moderna stocks.